BioCentury
ARTICLE | Company News

Exact Sciences, hedge fund spar over Cologuard

July 17, 2015 1:31 AM UTC

Exact Sciences Corp. (NASDAQ:EXAS) and hedge fund Cable Car Capital each proposed reimbursement rates for Cologuard at a CMS meeting to discuss 2016 payment levels for clinical tests.

The meeting follows a campaign by Cable Car to persuade CMS to narrow its coverage and reduce reimbursement levels for the non-invasive DNA screening test for colorectal cancer (CRC). Cable Car holds a short position in Exact Sciences (see BioCentury Extra, June 30). ...